Literature DB >> 23900784

An educational symposium for patients with sickle cell disease and their families: results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant.

Amanda L Thompson1, Alexis Bridley, Eileen Twohy, Jackie Dioguardi, Jane Sande, Lewis L Hsu, Naynesh Kamani, Emily Riehm Meier.   

Abstract

BACKGROUND: The only available cure for sickle cell disease (SCD) is hematopoietic stem cell transplant (HSCT). One important barrier to HSCT in SCD is lack of patient and family knowledge. PROCEDURE: To improve awareness of HSCT as a curative option for SCD, we hosted half-day educational symposia in 2011 and 2012. Symposia included didactic lectures by HSCT experts, small group sessions, and question and answer sessions with SCD patients and their families who had undergone HSCT. In 2011, we distributed anonymous pre- and post-symposium knowledge tests to determine how much attendees had learned about transplant. In 2012, we asked attendees to rate the importance of various medical and psychosocial factors in the decision to pursue HSCT.
RESULTS: Results from 2011 showed that knowledge about HSCT increased significantly after the symposium. Concern about the risk of transplant decreased slightly, but not significantly, following the symposium, and the majority of attendees expressed a desire to speak with physicians further about HSCT. In 2012, families reported that risk of death, prevention of SCD complications, and risk of serious complications were the most important considerations for their decisions about HSCT.
CONCLUSIONS: A half-day symposium for SCD patients and their families can increase knowledge about HSCT. Education about risks and benefits of HSCT is key, as families consider these medical factors to be most important to their decision to pursue transplant. Our symposia can be replicated across the country to increase knowledge about HSCT for SCD and impact the number of patients who pursue HSCT.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  hematopoietic stem cell transplant; sickle cell anemia

Mesh:

Year:  2013        PMID: 23900784     DOI: 10.1002/pbc.24704

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

Review 1.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

2.  The importance of long-term follow-up in pediatric hematopoietic stem cell transplantation.

Authors:  D A Jacobsohn
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

Review 3.  How I treat sickle cell disease with hematopoietic cell transplantation.

Authors:  Elizabeth O Stenger; Shalini Shenoy; Lakshmanan Krishnamurti
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

Review 4.  Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease.

Authors:  Emily Limerick; Allistair Abraham
Journal:  J Clin Med       Date:  2022-07-03       Impact factor: 4.964

Review 5.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

6.  The Future of Prenatal Diagnosis and Screening.

Authors:  Eugene Pergament
Journal:  J Clin Med       Date:  2014-11-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.